V
Velarion™Intelligence
Sign InFree TrialBook a Walkthrough
Biopharma & Life Sciences

CRISPR Therapeutics AG Executive Compensation (FY25)

CRSP · Executive and director compensation, fiscal 2022 to 2025
Chief executive, fiscal 2025
◇
Samarth Kulkarni
Latest say-on-pay support
=
June 4, 2026
Chief executive pay ratio
◇
To the median employee
Velarion Member: every covered company in Biopharma & Life Sciences, with dashboards, peer screens and board-ready briefs. Three seats, one year.

The CRISPR Therapeutics AG brief, $1,500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $2,400.
Get the executive briefGet the board briefNo account needed.
Data as of October 19, 2026Latest filing (8-K): June 4, 2026
14 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
CRISPR Therapeutics AG brief$1,500Get the executive brief
Velarion Member, one year
339 figures on this page: 333 cited to the filing that reported them, 6 calculated from figures it prints. See the citations
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Samarth Kulkarni: $33,175,626 → $7,678,477 (76.9% lower)
CEO pay ratio: 121:1 → 26:1 (78.5% lower)

Frequently asked questions

Answers drawn from the data on this page.
Who is CRISPR Therapeutics AG's chief executive and what were they paid?
Samarth Kulkarni, Chairman and Chief Executive Officer, received $7,678,477 in total compensation for fiscal 2025. Kulkarni's total moved 76.9% lower from the $33,175,626 reported for fiscal 2024.
What was CRISPR Therapeutics AG's say-on-pay result?
Shareholders supported the say-on-pay proposal with 69.4% of votes cast for or against in favor at the meeting held June 4, 2026 for fiscal 2025.
Which companies are in CRISPR Therapeutics AG's peer group?
The disclosed peer group includes Apellis Pharmaceuticals, Arrowhead Pharmaceuticals, Avidity Biosciences, Beam Therapeutics and Blueprint Medicines, among others.
What is CRISPR Therapeutics AG's chief executive pay ratio?
The disclosed chief executive pay ratio for fiscal 2025 is 26:1, against median employee compensation of $295,181.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Samarth Kulkarni
Chief Executive Officer
◇—◇◇◇—◇◇
Phuong Morrow
Chief Medical Officer
◇◇◇◇◇—◇◇
James Kasinger
General Counsel
◇—◇◇◇—◇◇
Lawrence Klein
Former Chief Operating Officer
Departed during or after this year
◇—◇◇——◇◇
Brendan Smith
Former Chief Financial Officer
Departed during or after this year
◇—◇◇◇—◇◇
Novak Rodger
Chairman
◇—————◇◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Samarth Kulkarni
Chairman and Chief Executive Officer
◇—◇◇◇—◇◇
Raju Prasad
Chief Financial Officer
◇◇◇◇◇—◇◇
James Kasinger
General Counsel
◇—◇◇◇—◇◇
Phuong Khanh Morrow
Former Chief Medical Officer
Departed during or after this year
◇—◇◇——◇◇
Rodger Novak
Former President and Chairman
Departed during or after this year
◇——◇———◇
Brendan Smith
Former Chief Financial Officer
Departed during or after this year
◇—————◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Samarth Kulkarni
Chairman and Chief Executive Officer
◇—◇◇◇—◇◇
Naimish Patel
Chief Medical Officer
◇◇◇◇◇—◇◇
James Kasinger
General Counsel and Secretary
◇—◇◇◇—◇◇
Raju Prasad
Chief Financial Officer
◇—◇◇◇—◇◇
Julianne Bruno
Former Chief Operating Officer
Departed during or after this year
◇—◇◇◇—◇◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Samarth Kulkarni
Chairman and Chief Executive Officer
◇—◇◇◇—◇◇
Naimish Patel
Chief Medical Officer
◇—◇◇◇—◇◇
Julianne Bruno
Former Chief Operating Officer
Departed during or after this year
◇—◇◇——◇◇
Raju Prasad
Chief Financial Officer
◇—◇◇◇—◇◇
James Kasinger
General Counsel and Secretary
◇—◇◇◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
James R. KasingerOPTION◇——◇—◇◇
James R. KasingerRSU◇——◇——◇
Julianne BrunoOPTION◇——◇—◇◇
Julianne BrunoRSU◇——◇——◇
Naimish PatelRSU◇——◇——◇
Naimish PatelRSU◇——◇——◇
Naimish PatelOPTION◇——◇—◇◇
Raju PrasadRSU◇——◇——◇
Raju PrasadRSU◇——◇——◇
Raju PrasadOPTION◇——◇—◇◇
Samarth KulkarniOPTION◇——◇—◇◇
Samarth KulkarniRSU◇——◇——◇
Fiscal 2022, 2023 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Raju PrasadRSU◇◇——
Option◇—◇3/14/2033
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇3/20/2034
Option◇—◇10/13/2033
Option◇—◇10/16/2034
Option◇—◇3/14/2035
Option◇—◇10/3/2035
Naimish PatelOption◇—◇10/16/2034
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇5/28/2034
Option◇—◇3/14/2035
Option◇—◇10/3/2035
Samarth KulkarniRSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇2/18/2032
Option◇—◇3/14/2035
Option◇—◇3/10/2033
Option◇—◇10/13/2033
Option◇—◇3/20/2034
Option◇—◇10/16/2034
Option◇—◇10/3/2035
James KasingerRSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇10/13/2033
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇2/18/2032
Option◇—◇10/7/2032
Option◇—◇3/10/2033
Option◇—◇3/20/2034
Option◇—◇10/16/2034
Option◇—◇3/14/2035
Option◇—◇10/3/2035
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Severance and change in control

The terms as written in the agreements.
Julianne Bruno
Former Chief Operating Officer · Employment agreement · citing a 2024 filing
Benefits continuation on change in control◇
Benefits continuation◇
Non-compete period◇
Non-solicit period◇
Naimish Patel
Chief Medical Officer · Employment agreement · citing a 2024 filing
Benefits continuation on change in control◇
Benefits continuation◇
Non-compete period◇
Non-solicit period◇
Clawback◇
Raju Prasad
Chief Financial Officer · Employment agreement · citing a 2023 filing
Benefits continuation on change in control◇
Benefits continuation◇
Non-compete period◇
Non-solicit period◇
Clawback◇
Samarth Kulkarni
Chairman and Chief Executive Officer · Employment agreement · citing a 2017 filing
Benefits continuation on change in control◇
Benefits continuation◇
Non-compete period◇
Non-solicit period◇

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Douglas A. Treco
◇—◇———◇
John T. Greene
◇—◇———◇
Katherine A. High
◇—◇———◇
Sandesh Mahatme
◇—◇———◇
Maria Fardis
◇—◇———◇
Ali Behbahani
◇—◇———◇
H. Edward Fleming Jr
◇—◇———◇
Simeon J. George
◇—◇———◇
Briggs W. Morrison
◇—◇——◇◇
Christian Rommel
◇—◇———◇
Samarth Kulkarni served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board equity retainer◇
Total board retainer◇
Board chair premium◇
Lead independent director premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇
Equity is delivered as Options.

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
  • Apellis Pharmaceuticals APLS
  • Arrowhead Pharmaceuticals ARWR
  • Avidity Biosciences RNAM
  • Beam Therapeutics BEAM
  • Blueprint Medicines BPMC
  • BridgeBio Pharma BBIO
  • Cytokinetics CYTK
  • Denali Therapeutics DNLI
  • Dyne Therapeutics DYN
  • Intellia Therapeutics NTLA
  • Ionis Pharmaceuticals IONS
  • Legend Biotech LEGN
  • Neurocrine Biosciences NBIX
  • Prothena PRTA
  • Revolution Medicines RVMD
  • Sarepta Therapeutics SRPT
  • Ultragenyx Pharmaceutical RARE
  • Vaxcyte PCVX
  • Vir Biotechnology VIR

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025June 4, 2026=◇◇◇
2024June 5, 2025=◇◇◇
2023May 30, 2024=◇◇◇
2021June 9, 2022=◇◇◇
2020June 10, 2021=◇◇◇
2017May 30, 2018=◇◇◇

Chief executive pay ratio

As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇

Velarion Pro: every company page, peer tools and exports, one seat

One seat, one person. It opens the whole platform: the peer tools, the written analysis and the exports, on every company we cover. Join the list and you will hear from us when it opens.
Your address is used for this and nothing else, and you can unsubscribe in one click. See the privacy policy.

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Samarth Kulkarni (Chairman and Chief Executive Officer), FY2025 total compensation $7,678,477 (base salary $768,622) [exec_comp, SEC accession 0001193125-26-165158, filed 2026-04-21]

Answered within 24 hours, every figure cited to its SEC filing. If our database cannot answer your question, you are refunded automatically.

Email me this page as a cited PDF — sent in 2 minutes
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when CRISPR Therapeutics AG files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact CRISPR Therapeutics AG disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where CRISPR Therapeutics AG sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $499
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Say-on-pay responsiveness
CRISPR Therapeutics AG recorded a low support level. The responsiveness analysis covers what the company said it would do, what it did, and how that compares with the companies that recovered their vote.
Responsiveness analysis
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for Peer Group Review
Whether CRISPR Therapeutics AG's disclosed peer group is defensible, who names CRISPR Therapeutics AG back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
339 figures on this page: 333 cited to the filing that reported them, 6 calculated from figures it prints.
333 cited to the filing
6 calculated from the filing

Documents cited

  1. 0001193125-26-257593
    Proposal 7 – Non-Binding Advisory Vote on the Compensation Paid to the Company’s Named Executive Officers Under U.S.
  2. 0001193125-26-165158
    CEO Pay Ratio · DIRECTOR COMPENSATION · Grants of Plan-Based Awards for Fiscal Year 2025 · Outstanding Equity Awards at Fiscal Year-End · and 1 more section
  3. 0000950170-25-083799
    Proposal 7 – Non-Binding Advisory Vote on the Compensation Paid to the Company’s Named Executive Officers Under U.S.
  4. 0000950170-25-054711
    Summary Compensation Table
  5. 0000950170-24-067660
  6. 0000950170-24-043025
    Summary Compensation Table
  7. 0000950170-23-014831
    Summary Compensation Table
  8. 0000950170-22-011570
  9. 0001564590-21-032800
  10. 0001193125-18-181922
    Item 5.07 Submission of Matters to a Vote of Security Holders
  11. 0000950123-24-005877
    EX-10.6
  12. 0000950170-24-090746
    EX-10.7
  13. 0000950170-23-007716
    EX-10.8
  14. 0001193125-17-300284
    EX-10.4
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “CRISPR Therapeutics AG executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/CRSP (accessed 2026).
Short form: data: Velarion

The CRISPR Therapeutics AG brief, $1,500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $2,400.
Get the executive briefGet the board briefNo account needed.
14 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about CRISPR Therapeutics AG and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Biopharma & Life Sciences rankings

Chief executive pay — Biopharma & Life SciencesCEO pay ratio — Biopharma & Life SciencesSay-on-pay support — Biopharma & Life Sciences

Peers CRISPR Therapeutics AG discloses

The companies named in CRSP's own disclosed peer group.

Apellis PharmaceuticalsArrowhead PharmaceuticalsBeam TherapeuticsBlueprint MedicinesBridgeBio PharmaCytokineticsDenali TherapeuticsDyne TherapeuticsIntellia TherapeuticsIonis PharmaceuticalsNeurocrine BiosciencesProthenaRevolution MedicinesSarepta TherapeuticsUltragenyx PharmaceuticalVaxcyteVir Biotechnology

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy